enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Beats Estimates By $0.91 EPS

enGene (NASDAQ:ENGN) issued its quarterly earnings results on Monday. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91, FiscalAI reports.

enGene Price Performance

ENGN stock opened at $1.62 on Monday. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a 12-month low of $1.40 and a 12-month high of $12.25. The company has a 50 day moving average of $4.41 and a two-hundred day moving average of $7.24. The company has a market cap of $108.52 million, a price-to-earnings ratio of -0.72 and a beta of -0.29.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ENGN shares. Wall Street Zen cut enGene from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. HC Wainwright decreased their price objective on shares of enGene from $25.00 to $6.00 and set a “buy” rating for the company in a report on Friday, May 8th. UBS Group cut their target price on shares of enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Citizens Jmp downgraded enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Finally, Weiss Ratings cut shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $12.68.

Institutional Trading of enGene

Several large investors have recently added to or reduced their stakes in ENGN. Millennium Management LLC raised its holdings in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Cresset Asset Management LLC acquired a new position in enGene during the second quarter worth $36,000. Paloma Partners Management Co bought a new position in enGene during the second quarter valued at about $38,000. Finally, Jump Financial LLC bought a new position in enGene during the fourth quarter valued at about $121,000. 64.16% of the stock is owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.